Participants collected genital swabs four times daily for quantitative HSV DNA PCR. Clinical data were masked from laboratory personnel. The primary endpoint was within-person comparison of shedding rate in each study group. Analysis was per protocol. The trials are registered at ClinicalTrials.gov (NCT00362297,
Results Of 113 participants randomised, 90 were eligible for analysis of the primary endpoint. Participants collected 23 605 swabs; 1272 (5.4%) were HSV-positive. The this website frequency of HSV shedding was significantly higher in the no medication group (n=384, 18.1% of swabs) than in the standard-dose aciclovir group (25, 1.2%; incidence rate ratio [IRR] 0.05, C646 solubility dmso 95% CI 0.03-0.08). High-dose aciclovir was associated with less shedding than standard-dose valaciclovir (198 [4.2%] vs 209 [4.5%]; IRR 0.79, 95% CI 0.63-1.00). Shedding was less frequent in the high-dose valaciclovir group than in the standard-dose valaciclovir group (164 [3.3%] vs 292 [5.8%]; 0.54, 0.44-0.66). The number of episodes per person-year did not differ significantly for standard-dose valaciclovir
(22.6) versus high-dose aciclovir (20.2; p=0.54), and standard-dose valaciclovir (14.9) versus high-dose valaciclovir (16.5; p=0.34), but did for no medication (28.7) and standard-dose aciclovir (10.0; p=0.001). Median episode duration was longer for no medication than for standard-dose aciclovir (13 h vs 7 h; p=0.01) and for standard-dose valaciclovir than for high-dose valaciclovir (10 h vs 7 h; p=0.03), but did not differ significantly between standard-dose valaciclovir and high-dose aciclovir (8 h vs 8 h; p=0.23). Likewise, maximum log 10 copies of HSV detected per mL was higher for no medication than for standard-dose aciclovir (3.3 vs 2.9; p=0.02), and for standard-dose valaciclovir than for high-dose valaciclovir (2.5 vs 3.0; p=0.001), but no significant difference was recorded for standard-dose valaciclovir versus high-dose aciclovir (2.7 vs 2.8; p=0.66). 80% of episodes were subclinical in all study groups. Except
for a higher frequency of headaches with high-dose valaciclovir (n=13, 30%) than with other regimens, all regimens were well tolerated.
Interpretation Short bursts 4-Aminobutyrate aminotransferase of subclinical genital HSV reactivation are frequent, even during high-dose antiherpes therapy, and probably account for continued transmission of HSV during suppressive antiviral therapy. More potent antiviral therapy is needed to eliminate HSV transmission.”
“Modern factor analysis is the outgrowth of Spearman’s original “”2-factor”" model of intelligence. according to which a mental test score is regarded as the sum of a general factor and a specific factor. As early as 1914, Godfrey Thomson realized that the data did not require this interpretation and he demonstrated this by proposing what became known as his “”bonds”" model of intelligence. Van der Maas et al.